- Continuing Friday's rally, Jaguar Health Inc (NASDAQ: JAGX) stock has surged on Monday as the investors react to the news of its third royalty financing agreement announced on Friday.
- The company entered a binding term sheet for $5 million a royalty interest in future potential crofelemer (Mytesi) sales for the proposed COVID-related indication in long-hauler patients.
- JAGX is currently pursuing conditional marketing authorization in the European Union.
- This financing follows two royalty transactions, including $5 million announced in October and $6 million finalized in December.
- Price Action: On the last check, JAGX surged 48.8% at $2.39 in market trading hours.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
